Premium
Vulvovaginal C andida albicans infections: pathogenesis, immunity and vaccine prospects
Author(s) -
Cassone A
Publication year - 2015
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.12994
Subject(s) - vulvovaginal candidiasis , candida albicans , corpus albicans , immunology , immunity , etiology , immune system , medicine , pathogenesis , microbiology and biotechnology , clinical trial , biology
Although a number of fungal species belonging to the genus C andida can cause acute vulvovaginal infection ( VVC ), C andida albicans is by far the most prevalent etiological agent, particularly for the most severe chronic condition known as recurrent vulvovaginal candidiasis ( RVVC ). This review focuses on recent advances in pathogenic mechanisms and host immune responses to C . albicans and on the utilisation of this information in the development of a vaccine to prevent and/or treat vaginal candidiasis. Currently, two vaccines with main or sole RVVC as clinical indication have completed a phase 1 clinical trial, and one of them has entered a phase 2 trial.